Hypertriglyceridaemia and elevated cardiovascular risk: will ANGPTL4 inhibition address both?
1. 请及时下载文件确认是否正确, 系统将在 2026-01-27 16:56:35 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
JL Katzmann, U Laufs
2025
academic.oup.com
Comment to:'Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies' by Cummings BB et al.(Lancet 2025; 405: 1923–1934) In the last decade, the armamentarium of therapeutic options to modify lipoprotein metabolism has substantially expanded. The discovery of novel targets involved in lipoprotein metabolism such as proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein CIII (apo CIII), lipoprotein (a), and angiopoietin-like 3 (ANGPTL3) was one …
